TELA Bio director receives 16,089 shares as pay

The compensation was delivered as fully vested common shares rather than cash under the director compensation policy.

Rhea-AI Filing Summary

TELA Bio, Inc. director William J. Plovanic acquired 16,089 shares of common stock on October 15, 2026, issued in lieu of cash compensation under the company's Amended and Restated Non-Employee Director Compensation Policy. The shares were fully vested. The reported transaction price was $1.01 per share, and his direct holdings following the transaction were 60,619 shares.

Insider Trade Summary

Grant/Award: 16,089 shares

Grant/Award 1 txn

Insider Plovanic William J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	16,089	$1.01	$16K

Holdings After Transaction: Common Stock — 60,619 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock issued in lieu of cash compensation under the Issuer's Amended and Restated Non-Employee Director Compensation Policy. All shares are fully vested.

Key Figures

Common shares acquired: 16,089 shares Reported transaction price per share: $1.01 per share Direct holdings following transaction: 60,619 shares

3 metrics

Common shares acquired 16,089 shares October 15, 2026; issued in lieu of cash compensation

Reported transaction price per share $1.01 per share October 15, 2026 transaction

Direct holdings following transaction 60,619 shares Common stock

Key Terms

Amended and Restated Non-Employee Director Compensation Policy, fully vested, in lieu of cash compensation

3 terms

Amended and Restated Non-Employee Director Compensation Policy financial

"under the Issuer's Amended and Restated Non-Employee Director Compensation Policy"

fully vested financial

"All shares are fully vested"

in lieu of cash compensation financial

"shares of common stock issued in lieu of cash compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did TELA director William J. Plovanic receive?

William J. Plovanic received 16,089 shares of common stock on October 15, 2026, in lieu of cash compensation under the Amended and Restated Non-Employee Director Compensation Policy; the shares were fully vested. The reported transaction price was $1.01 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/19/2026 - 05:07 PM EDT Accepted by SEC EDGAR 10/19/2026 - 05:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plovanic William J.

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2026		A		16,089(1)	A	$1.01	60,619	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of cash compensation under the Issuer's Amended and Restated Non-Employee Director Compensation Policy. All shares are fully vested.

	/s/ Megan Smeykal, Attorney-in-Fact	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)